Bora Pharmaceuticals Exits Integration Phase with Sequentially-Improved Gross and Operating Margins
Positioned to Unlock M&A Value through U.S. Manufacturing Amidst Geopolitical Complexities and Specialty Portfolio
Quarterly Business and Financial Highlights
Fueled by expanded capacity and new dosage forms, Bora's CDMO business delivered a record high quarter, up 52.4% YoY and 3.0% QoQ.
As part of Bora's long-term strategic growth plan, the Company is moving forward with a phased investment of tens of thousands US dollars to unlock the untapped potential of Maple Grove facility. This build-out is designed to enhance capabilities in oral solid dose and sterile manufacturing, strengthening the ability to support customer demand and scale future programs.
Pharma Sales revenues rose 82.0% YoY based on reported unaudited monthly sales, driven by strong performance from the vigabatrin franchise, which includes three dosage forms. Notably, VIGAFYDE captured over 70% share in the new patient segment.
Due to the completion of Plymouth area decommissioning, consolidated revenues for 1Q25 was NT$4.48 billion, a NT$350 million reversal from the unaudited monthly disclosures, all of which was attributed to the pharma sales segment.
Despite margin pressure from partial maintenance shutdowns at the Maryland sterile injectable site in early January and softening demand for generic product dexlansoprazole (DLS), product mix improvement from growing specialty portfolio lifted gross margin from the low of 4Q24 to 42.2% in 1Q25. Tech transfer for 6 Upsher-Smith generic products to cost-competitive sites within Bora network remains on track, with full transfer expected by year-end to support further margin recovery.
EPS from continuing operations reached NT$26.54, reflecting NT$2.44 billion of net non-operating income from the divestment of Bora Biologics and recognition of losses of Tanvex Biopharm. However, the decommissioning of the Plymouth area negatively impacted EPS by NT$12.99, resulting in a reported EPS of NT$13.55. Share capital increased 0.4% during the quarter from employee stock option exercises and convertible bond conversions.
DLS competitors began exiting the market in early 2Q25 due to supply chain hiccups, creating new opportunities for Bora to increase share and drive recovery momentum.
The Group remains optimistic that its first quarter restructuring efforts will increase the long-term value of its recent acquisitions, including unlocking NT$600 million in capital in 2025. CDMO business growth will be further accelerated with strategic U.S.-based capability and capacity.
Mr. Bobby Sheng, Chairman of Bora Group, stated, "The first quarter is the continuation of critical integration and restructuring phase following multiple business and capacity acquisitions in 2024, laying a solid foundation for operational efficiency expansion. Following substantial investments in the U.S last year, we did observe significant pressure in the U.S. generics space during Q4. This prompted us to swiftly accelerate our integration efforts. At the same time, evolving client dynamics and market demand have only strengthened our conviction in the long-term value and strategic role of these assets. While the organizational streamlining, business separation, and product portfolio optimization undertaken to reflect operational realities have created near-term hurdles, we remain confident that these actions are essential to achieving optimal resource allocation and hence satisfactory return on assets. These efforts are necessary steps in the Company's path toward sustainable mid to long-term growth.
The closure of Plymouth area was completed ahead of schedule during the quarter and the area has thus been reclassified as discontinued operation in our quarterly financial statements altogether. From an operational standpoint, Bora has discontinued 15 products in the U.S. generics market along with the restructure, with an additional 6 products transferred to more cost-efficient manufacturing sites within the Group. On the financial side, discontinued operation resulted in a negative impact of approximately NT$1.34 billion, including overhead, inventory and equipment write-downs as well as severance-related expenses.
Looking ahead, Bora will advance its focus on high-value and complex dosage forms supported by over NT$5.0 billion cash on hand. At Maple Grove, 4 global pharmaceutical clients are currently in advanced discussions regarding CAPEX investments which we view as a strong validation of the site's value and strategic fit. While the timeline for full deployment spans several years, we are approaching this expansion with operational discipline and commercial alignment to ensure its success over time.
On pharma sales side, Bora weathered softness in DLS demand in the first quarter but quickly gained market share as a competitor exited in early second quarter. Generic business rebounded in April, supported by strong sales from new 2024 launches including Potassium Chloride ER Tablets (KCL), and anti-angina drugs Diltiazem (DTC and DTS). This recovery underscores Bora's agility and the resilience of the dual-engine strategy. Furthermore, we have successfully consolidated distribution network for specialty drugs. Bora expects its pediatric spasm product, VIGAFYDE (the 505(b)(2) oral solution), to extend its success in the new patient market into the switch segment in the very near future, supporting future margin and operational leverage expansion.
1Q2025 Operational Achievements & Full Year Outlook
Global CDMO Operations
In 1Q25, the small molecule CDMO pipeline added US$123 million in potential orders and US$78 million in backlog, both marking historic highs.
CAPEX progress across sites reached approximately 50%, focused on debottlenecks, efficiency improvement, capacity increase and infrastructure upgrade to align with client and product needs. Flex Pro line at the Maryland sterile injectable facility was completed ahead of schedule and is expected to begin operations in early Q3.
Maple Grove launched its first CDMO project during the quarter and is currently negotiating with potential clients while evaluating CAPEX plans for differentiated dosage platforms. Overall, North American capacity transformation is progressing as planned.
Large molecule CDMO operation was launched following the January 20 reverse-acquisition of Bora Biologics by Tanvex Biopharm where Bora owns 30.5% of Tanvex. CDMO operations at the San Diego site are now active, and the ongoing 2,000L expansion has received strong interest from late-stage clients. Bora and Tanvex are actively pursuing U.S.-based commercial-scale manufacturing orders with a comprehensive one-stop service model.
As the Upsher-Smith team continue to consolidate distributors for specialty drugs, we saw early signs of positive engagement from both market and payer channels at the end of the first quarter. Following the 2024 integration of TWi, Upsher-Smith and Pyros teams, Bora has established a focused pipeline in CNS specialty areas. The company expects to file its first self-developed 505(b)(2) submission for infantile spasms (Stiripentol) with the U.S. FDA by year-end, alongside other pipeline developments.
Pediatric epilepsy and TSC-related rare diseases represent the first wave of Bora's pharma sales transformation targets. In addition to reducing over-reliance on generics, high-value rare disease and specialty drugs benefit from strong regulatory and payer support in the specialty pharmacy channel. These markets are less competitive with stable price, and offer targeted access to patient populations, allowing for meaningful long-tail value creation.
Recent Investor Conference
Bora 2025 Earnings Schedule
HONG KONG SAR - Media OutReach Newswire - 14 May 2025 - Bora Pharmaceuticals (TWSE: 6472) today announced itsWe continue executing on our goals to scale up, achieve more and integrate smarter, ensuring that both internal and external clients benefit from cost-efficient, regionally aligned manufacturing. By extending the strength of our dual-engine model, we believe Bora shall continue to create above-average total shareholder return."Global CDMO Operations (excluding internal orders) delivered record-high revenues of NT$1.90 billion in the first quarter, up 52.4% YoY and representing approximately 39% of total revenue. Including internal orders, CDMO revenue reached NT$2.89 billion. A total of 600 million doses were developed and manufactured. Revenue contribution from global top 20 pharmaceutical companies remained steady at approximately 30%, demonstrating strong clientele and advantage of scale. Bora CDMO continues to be a trusted partner for biotech and pharmaceutical innovators.Pharma Sales Operations revenue reached NT$2.93 billion, representing 82.0% YoY growth and contributing approximately 61% of total revenue based on unadjusted numbers.Bora will host an English online earnings call at 7:00 a.m. Taiwan time on May 15, 2025, followed by an investor conference hosted by Taishin Securities at the Grand Hyatt Taipei at 2:00 p.m. on May 16, 2025. Both events will cover the company's Q1'25 financial and business results and outlook.English Online Earnings Presentation Link: https://www.zucast.com/event/54SiM5il/subscribe/create The 2025 Annual General Shareholders' Meeting will be held on May 23 at the Tainan Guantian Industrial Marketing Center.Bora will participate in the Jefferies Global Healthcare Conference in New York on June 4–5. For 1:1 meetings with management, please contact your Jefferies representative.Q2 2025: Expected in the 3week of August 2025Q3 2025: Expected in the 3week of November 2025Q4 2025: Expected in the 2week of March 2026Hashtag: #Bora
The issuer is solely responsible for the content of this announcement.
About Bora
Founded in 2007, Bora Pharmaceuticals ("Bora" or "the Company", 6472.TW) is a leading pharmaceutical services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life.
By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success "certain," Bora sets new standards in the pharmaceutical and CDMO industries.
For more, please visit:
https://www.bora-corp.com
https://www.boracorpcdmo.com
Disclaimer:
This document and the accompanying information may contain forward-looking statements. All statements regarding the company's future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company's control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malay Mail
5 hours ago
- Malay Mail
Beyond the recycling bin: Why Gen Z is putting employers' green cred to the test — Elman Mustafa El Bakri
JUNE 6 — Putting a recycling bin in the pantry doesn't make you a green company anymore. That may have been acceptable a decade ago, but today's workforce — particularly Gen Z — is far more discerning. They are no longer content with symbolic gestures. When it comes to the environment, they expect substance, transparency, and accountability. According to LinkedIn, 74 per cent of Gen Z find it crucial to work at companies that reflect their values, and 87 per cent are willing to switch jobs if the employer's values do not align. They want transparency on environmental policies alongside diversity, equity, and inclusion. And according to a 2024 article, Gen Z looks for employers who provide meaningful sustainability initiatives, such as reducing carbon footprints, committing to net-zero emissions, offering sustainable products, and providing sustainability training. They want these efforts embedded in company culture, not just as PR. For many years, employers have been the ones leading the conversation during job interviews. But that dynamic is shifting. Increasingly, Gen Z candidates are the ones asking the more profound questions: 'What does this organisation stand for?' And for a growing number of them, one of the first filters is a company's environmental stance. Environmental responsibility can no longer be confined to an annual CSR campaign or a glossy page in a sustainability report. This generation is not simply seeking jobs — they are seeking alignment. They want to work in spaces that reflect their values, including a sincere commitment to the planet they hope to protect. And while these questions may not come in the form of a checklist, the audit is real. Gen Z professionals are asking how seriously companies take their environmental footprint. They pay attention to how a business sources its materials, whether hybrid or remote work is genuinely encouraged, and whether any sustainability claims are backed by evidence. They are not looking for perfection, but they are looking for intention. They want to see the work behind the words — the plan behind the promises. What distinguishes this shift is not just the demand for environmental action, but the demand for consistency. To Gen Z, sustainability is not about compliance or marketing. It's cultural. It reflects how decisions are made, who gets involved, and whether those decisions are aligned with long-term thinking rather than short-term image. This is why surface-level efforts — such as replacing plastic cups or holding a one-off 'green day' — often fall flat. Gen Z professionals are informed, connected, and aware of the deeper issues at stake. Performative actions are easily spotted. And once a company loses that trust, it is difficult to regain. In my role working across both industry and academia, I've observed how environmental expectations are quickly becoming part of the employer brand. It's no longer just about salaries, perks, or even work-life balance. Increasingly, it's also about environmental credibility. And companies that don't keep up may find themselves struggling not only to attract talent, but to retain it. The good news is that there is space for progress. You don't need to have all the answers today, but you do need to be asking the right questions. Organisations can begin by understanding their environmental footprint — energy usage, waste patterns, procurement habits — and identifying where change is both needed and possible. Integrating sustainability into operational decisions, enabling more climate-conscious policies such as hybrid work arrangements, and engaging staff in ongoing environmental initiatives are all meaningful steps. Equally important is the culture of inclusion. Young professionals should be given the opportunity to participate in shaping sustainability efforts, rather than simply being expected to follow them. Progress is far more likely when employees feel they are part of the solution. And whatever the starting point, transparency matters. Admitting that there is still work to be done is not a weakness — it is often seen as a strength. At its core, this is not about appeasing a generation. It is about evolving with the times. The environmental expectations of Gen Z reflect a broader shift in how work is perceived. Employment is no longer just a transaction — it is an extension of identity and purpose. And businesses that understand this shift will be better positioned to lead in the future. As we mark World Environment Day 2025, it is worth asking ourselves: What kind of workplace are we building? Is it one that future employees would be proud to join — not just because of what we do, but because of how we choose to do it? In an age where values drive choices, where integrity is visible, and where climate action is no longer optional, the organisations that lead with purpose will also lead in performance. Because in the end, it's not just about attracting talent. It's about earning their belief. * The author is CEO and Founder of HESA Healthcare Recruitment Agency and serves on the Industrial Advisory Panel for the Department of Biomedical Engineering, Universiti Malaya. He may be reached at [email protected] ** This is the personal opinion of the writer or publication and does not necessarily represent the views of Malay Mail.
Malay Mail
6 hours ago
- Malay Mail
OpenAI fights back in NYT copyright lawsuit over ChatGPT data freeze
NEW YORK, June 6 — OpenAI is appealing an order in a copyright case brought by the New York Times that requires it to preserve ChatGPT output data indefinitely, arguing that the order conflicts with privacy commitments it has made with users. Last month, a court said OpenAI had to preserve and segregate all output log data after the Times asked for the data to be preserved. 'We will fight any demand that compromises our users' privacy; this is a core principle,' OpenAI CEO Sam Altman said in a post on X yesterday. 'We think this (the Times demand) was an inappropriate request that sets a bad precedent.' US District Judge Sidney Stein was asked to vacate the May data preservation order on June 3, a court filing showed. The New York Times did not immediately respond to a request for comment outside regular business hours. The newspaper sued OpenAI and Microsoft in 2023, accusing them of using millions of its articles without permission to train the large language model behind its popular chatbot. Stein said in an April court opinion that the Times had made a case that OpenAI and Microsoft were responsible for inducing users to infringe its copyrights. The opinion explained an earlier order that rejected parts of an OpenAI and Microsoft motion to dismiss, saying that the Times' 'numerous' and 'widely publicised' examples of ChatGPT producing material from its articles justified allowing the claims to continue. — Reuters
Malay Mail
8 hours ago
- Malay Mail
US adds Ireland, Switzerland to currency watchlist in first Trump-era report
WASHINGTON, June 6 — The US Treasury Department said yesterday in a semi-annual report that no major trading partner was a currency manipulator in 2024, although it added Ireland and Switzerland to a monitoring list. The release of the currency report — the first of US President Donald Trump's new administration — took aim at China however for a 'lack of transparency around its exchange rate policies and practices.' The report looks into countries with large trade surpluses with respect to the United States, and those whose actively intervene in foreign exchange markets to gain a competitive edge. The Treasury found that no major partner manipulated currency exchange last year for reasons including gaining unfair trade advantages. But nine economies are on the Treasury's 'monitoring list' — signalling their currency practices and economic policies call for closer attention. The list includes China, Japan, South Korea, Taiwan, Singapore, Vietnam, Germany, Ireland and Switzerland — with Ireland and Switzerland being the new additions since November. 'We will continue to strengthen our analysis of currency practices and increase the consequences of any manipulation designation,' US Treasury Secretary Scott Bessent said in a statement. 'Moving forward, Treasury will use all available tools at its disposal to implement strong countermeasures against unfair currency practices,' he added. While the Treasury held off designating China as a currency manipulator, it warned that the situation could change if there was evidence suggesting the country was intervening to resist the appreciation of the yuan. The Treasury took aim at unfair currency practices abroad, saying they had contributed to the US trade deficit and 'hollowed out' manufacturing employment. — AFP
